Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8773482 | 0.81 | MEN1 (0.69) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL17258003 | 0.79 | MEN1 (0.54) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL2198151 | 0.78 | TSHR (0.48) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL567235 | 0.76 | KMT2A (0.54) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL18038595 | 0.76 | KMT2A (0.54) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL20163753 | 0.75 | MEN1 (0.53) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL12536455 | 0.74 | MEN1 (0.65) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL17258048 | 0.74 | KMT2A (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL250885 | 0.73 | CES1 (0.53) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL2875452 | 0.72 | MEN1 (0.50) | MEN1KMT2AHTTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7915271-B2 | 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | CETP, MTTP, APOB | MEN1 4049/4885KMT2A 2516/4885HTT 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.